CD38 and Miyoshi myopathy: Idecabtagene vicleucel (ide-cel) was initially approved based on the results of the KarMMa study for the treatment of patients with relapsed or refractory MM after four lines of therapy with prior exposure to an immunomodulatory drug (IMiD), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb).